GlobeNewswire

Whitepages Pro Spins Off and Becomes Ekata

Del

Ekata’s Digital Identity Verification APIs Improve Predictability of Good Transactions

SEATTLE, June 12, 2019 (GLOBE NEWSWIRE) -- Whitepages Pro, the leader in global digital identity verification data, today announced that it is spinning off its B2B business from the US-focused direct-to-consumer operations of Whitepages.com. Whitepages Pro will change its name to Ekata to better differentiate the company’s global B2B APIs and SaaS tool that serve the growing worldwide need for identity verification, a market projected by McKinsey to reach $20 billion in 2022. To further these efforts, the business opened a new HQ for European operations earlier this year in Amsterdam, Netherlands. This second EU office will support sales, account management and marketing efforts in EMEA.

“Our new brand and independent operations reflect the integral role we play in helping many of the world’s biggest digital commerce businesses link a digital identity back to a human,” said Rob Eleveld, Ekata CEO. “Top brands, including Airbnb, Microsoft and Stripe leverage our identity verification product suite in their machine learning models, decisioning platforms, and for their manual review teams to approve good transactions, reduce customer friction, and catch fraud. Our additional European presence is built to serve the needs of the European markets, as well as other North American businesses expanding their global reach.”

Ekata’s solutions help businesses grow and scale revenue by maximizing the predictability of good transactions. From pre-authorization payment models through to manual review, the Ekata identity verification product suite is powered by Ekata Identity Engine (EIE), the first and only cross-border identity data engine of its kind.

Ekata’s industry leading approach of a single global endpoint is the new standard in true cross-border identity verification. It is trusted by ten of the largest U.S. online retailers, the top three global online travel and hospitality sites, two major credit card brands, top five fraud platforms, and many more.

Customers can select from Ekata’s powerful APIs for models and decisioning platforms or Pro Insight, a SaaS solution for manual review, all powered by Ekata’s Identity Engine that delivers performance that can meet the most demanding requirements, including identity data in under 100 milliseconds (ms) to improve machine learning (ML) model performance.

The EIE, which powers the identity verification suite, includes Ekata’s:

Proprietary network – Monitors linkages and associations across billions of data elements to identify real-time predictable patterns that correspond to the behavior of genuine customers versus those of fraudulent actors. Transaction queries are analyzed through complex machine learning algorithms that derive unique velocity, popularity, and volatility features to improve product performance by maximizing predictive lift.

Global graph – Houses more than 8 billion identity links that provide unparalleled global coverage and accuracy. From more than 50 authoritative sources, Ekata uses sophisticated data science to curate and corroborate the links between email, phone, name (person or business), physical address and IP to connect digital and physical identity attributes together.

The Connective IGA stack – Delivers the most predictive attributes to customers in less than 100ms. Leverages proprietary ingestion, generation and acceleration (IGA) processes to enable a single global endpoint and improve the speed and quality of responses.

Customers in Europe interested in learning how to grow and scale revenue by maximizing their ability to predict good transactions, can contact the Ekata team in Amsterdam at +31 20 240 34 50 and emeasales@ekata.com. Additional country contacts can be found on the company’s website.

Whitepages, Inc., founded by Alex Algard, has offered consumer and business solutions for digital contact and identity data for more than 25 years. Both Whitepages.com and Ekata will maintain their Seattle headquarters as they each focus on building the next-generation of solutions for their respective consumer and business audiences.

About Ekata
Ekata (formerly Whitepages Pro) provides global identity verification solutions via enterprise-grade APIs for automated decisioning, and Pro Insight, a SaaS solution for manual review for cross-border businesses to grow revenue by maximizing their predictability of good transactions. Our product suite is powered by the Ekata Identity Engine (EIE), the first and only cross-border identity verification engine of its kind. It uses complex machine learning algorithms across the five core consumer attributes of email, phone, name (person or business), physical address, and IP, to derive unique links and features from billions of real-time transactions within our proprietary network and the data we license from a broad spectrum of global providers. Businesses around the world including Alipay, Microsoft, Stripe, and Airbnb leverage our product suite to increase approvals of more good transactions, reduce customer friction, and find fraud.

Ekata is a trademark of Whitepages, Inc. All other trade names, trademarks and registered trademarks are the property of their respective owners.

Ekata Media Contact:
Lindsay Stril, Voxus PR
lstril@voxuspr.com
253-444-5443

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress15.6.2019 16:00:00 CESTPressemelding

CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced updated data from its Phase 2 PLAUDIT study of APL-2 in patients with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA). Data from the PLAUDIT trial will be presented in an oral presentation today at the 24th Annual Congress of the European Hematology Association (EHA), held in Amsterdam, the Netherlands. In the ongoing PLAUDIT study, 13 patients with CAD have been enrolled to receive subcutaneous APL-2 treatment, of which 10 patients have been on APL-2 for at least 168 days. The trial has also enrolled 11 patients with wAIHA, 8 of which were Direct Antiglobulin Test (DAT) C3+ (C3+ wAIHA); 5 of the C3+ wAIHA patients

Carpenter Technology and BMT Aerospace Combine Expertise in Redesign and Production of Additively Manufactured Aerospace Component14.6.2019 15:17:00 CESTPressemelding

LE BOURGET, France, June 14, 2019 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE:CRS) and Belgium-based BMT Aerospace today announced their cooperation in the development of an additively manufactured (AM) aerospace pinion, using Carpenter Technology’s Custom 465® Stainless. BMT Aerospace and its subsidiary BMT Additive initiated the project by partnering with Carpenter Technology to produce a redesigned pinion. The redesign project was initiated to enable the benefits of additive manufacturing using high quality, printable material that would attain the high-performance expectations for the application. “BMT Aerospace strongly believes in the disruptive potential of additive manufacturing and its possibilities in aerospace,” explained Ewald Goossens, Business Unit Manager of BMT Additive. “As a small player in the market, we strongly believe in cooperation opportunities like these, where each partner can rely and build on a project, starting from its own expertise. Our spe

Immunophotonics and Clinical Laserthermia Systems Announce Immuno-Oncology Research Collaboration and Clinical Trials for Cancer Patients with Solid Tumors14.6.2019 13:00:00 CESTPressemelding

Collaboration will Combine Immunophotonics’ Proprietary Drug, IP-001, and CLS’s TRANBERG Laser Thermal Therapy System and imILT Method ST. LOUIS and LUND, Sweden, June 14, 2019 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. and Clinical Laserthermia Systems, AB (STO:CLS B) (CLS) today announced they have entered into a research collaboration agreement to support a Phase 1b/2a clinical trial for cancer patients with certain solid tumor indications. The research will utilize each company’s respective products and methodologies during treatments and is intended to support early phase clinical trials facilitated by a leading clinical organization. Eligible patients with solid tumors will be treated using the locally administered CLS Immunostimulating Interstitial Laser Thermotherapy (imILT) method, followed immediately by an intratumoral injection of Immunophotonics’ lead asset, IP-001. Under the agreement, the CLS TRANBERG Laser and single-use products will be used in eligible patients enrolle

iCAD Introduces ProFound AI™ for 2D Mammography in Europe13.6.2019 14:00:00 CESTPressemelding

Company to showcase its newest artificial intelligence software solution, ProFound AI for 2D Mammography, in addition to ProFound AI for Digital Breast Tomosynthesis at the SIFEM Medical Conference in France NASHUA, N.H. and LILLE, France, June 13, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the launch of ProFound AI™ for 2D Mammography in Europe. This software is the latest addition to iCAD’s deep-learning, artificial intelligence platform and follows the launch of ProFound AI™ for Digital Breast Tomosynthesis (DBT), which was CE Marked in March 2018 and FDA cleared in December 2018. ProFound AI for 2D Mammography and ProFound AI for DBT will both be featured in the iCAD exhibition booth (#24) at the Société Française d'Imagerie de la FEMme (SIFEM) medical conference from June 13-15, 2019 at the Grand Palais in Lille, France. “iCAD is at the forefront of the fight ag

Telix Pharmaceuticals and Eczacıbaşı-Monrol Sign Manufacturing and Distribution Agreement13.6.2019 13:54:00 CESTPressemelding

MELBOURNE, Australia and ISTANBUL, Turkey, June 13, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR) has today announced that it has concluded a master services and distribution agreement with Eczacıbaşı-Monrol. Under the terms of the agreement, Telix has appointed Eczacıbaşı-Monrol as a radiopharmaceutical production partner and distributor in Turkey/Middle East/North Africa. Eczacıbaşı-Monrol is commercially active in more than 40 countries, including important growth territories that complement Telix’s current commercial strategy for the US and Europe. The parties will initially focus on the production and distribution of TLX250-CDx (89Zr-girentuximab) for imaging of renal cell carcinoma with Positron Emission Tomography (PET), including to support the ad

Highly Accurate Long-Read Sequencing of Human Genomes Leads to Discovery of Disease-Causing Variants13.6.2019 13:30:00 CESTPressemelding

Identification of pathogenic structural variants with SMRT Sequencing improves solve rate for rare and Mendelian diseases MENLO PARK, Calif., June 13, 2019 (GLOBE NEWSWIRE) -- While DNA sequencing tools have been useful for determining the genetic cause of many diseases, there remain a large number that are left unexplained. Recently, scientists have adopted Single Molecule, Real-Time (SMRT®) Sequencing from Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, to study previously unsolved diseases. Many high-impact research publications report expanded variant detection in human genomes, leading to discovery of disease-causing variants and genes underlying rare and Mendelian disorders. In a Nature Communications publication, scientists report that most structural variants (SVs) and large indels are undetected in today’s human genetic studies, which likely accounts for some of the missing heritabi